Penumbra (PEN) Receiving Somewhat Positive Media Coverage, Accern Reports
News coverage about Penumbra (NYSE:PEN) has trended somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Penumbra earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news headlines about the company an impact score of 47.8984365716661 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the headlines that may have effected Accern Sentiment’s scoring:
- Penumbra, Inc. (NYSE:PEN) Valuation in Focus (vassarnews.com)
- Price Target in Focus For Penumbra, Inc. (NYSE:PEN) (cantoncaller.com)
- Bounding Shares, What’s Next for Penumbra, Inc. (NYSE:PEN)? (cantoncaller.com)
- Penumbra Inc (PEN): Examining Today’s Signals (zeelandpress.com)
- Daniel Donen Davis Sells 7,500 Shares of Penumbra Inc (PEN) Stock (americanbankingnews.com)
Shares of Penumbra stock opened at $129.10 on Friday. Penumbra has a 52-week low of $82.55 and a 52-week high of $167.35. The stock has a market cap of $4.45 billion, a PE ratio of -12,910.00, a PEG ratio of 24.42 and a beta of 0.15.
PEN has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded shares of Penumbra from a “hold” rating to a “strong-buy” rating and set a $176.00 price target on the stock in a research note on Thursday, June 21st. Wells Fargo & Co reiterated an “outperform” rating and set a $180.00 price target (up from $150.00) on shares of Penumbra in a research note on Thursday, May 31st. ValuEngine upgraded shares of Penumbra from a “hold” rating to a “buy” rating in a research note on Wednesday, May 9th. BMO Capital Markets boosted their price target on shares of Penumbra from $115.00 to $140.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 9th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $175.00 price target on shares of Penumbra in a research note on Monday, August 20th. Three analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Penumbra presently has a consensus rating of “Buy” and a consensus target price of $158.60.
In related news, EVP Robert D. Evans sold 10,000 shares of the business’s stock in a transaction dated Monday, August 6th. The shares were sold at an average price of $150.16, for a total transaction of $1,501,600.00. Following the sale, the executive vice president now owns 15,667 shares of the company’s stock, valued at $2,352,556.72. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Daniel Donen Davis sold 7,500 shares of the business’s stock in a transaction dated Thursday, July 26th. The stock was sold at an average price of $144.43, for a total transaction of $1,083,225.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 49,054 shares of company stock worth $6,890,829. 10.70% of the stock is owned by insiders.
Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands.
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.